Navigation Links
Beaumont Health System launches research trial of bioresorbable heart scaffold
Date:7/29/2013

Beaumont Health System has joined a multicenter, international research study of a new temporary heart device that helps keep an artery open following angioplasty, then is broken down and absorbed by the body.

The research will compare the effectiveness of the new "disappearing" device, the AbsorbTM Bioresorbable Vascular Scaffold made by health care company Abbott, with drug-eluting, metal stents that are commonly placed in heart arteries as a permanent implant. Absorb is referred to as a scaffold to indicate it is temporary in nature, unlike a permanent metallic stent. It is made of polylactide, a material commonly used in medical implants such as dissolving sutures. Coronary artery stents were approved for use in the United States in 1994. Similar to a mesh tube, stents prop open a heart artery after a blockage is cleared with a procedure called angioplasty.

In angioplasty, a doctor threads a catheter, or hollow tube, into the arteries of the heart through a small incision in the groin or wrist, with a tiny balloon at its tip that, once inflated, pushes a blockage against the artery wall to open the artery and improve blood flow to the heart. Angioplasty is often followed by insertion of a stent coated with medication, called a drug-eluting stent, at the site of the blockage to keep the vessel open and prevent renarrowing. Metallic stents are a permanent implant in the wall of the artery.

"Stents have revolutionized the treatment of heart blockages by helping many patients to avoid having repeat angioplasty procedures and in some cases open-heart surgery," says Amr Abbas, M.D., Beaumont's director of interventional cardiology research and the study's principal investigator. "This new bioabsorbable vascular scaffold is the latest technique in heart treatment in interventional cardiology."

Research has shown that the support of a coronary stent is only needed for a few months after implantation while the artery wall is
'/>"/>

Contact: Angela Blazevski
angela.blazevski@beaumont.edu
248-551-0445
Beaumont Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
2. Beaumont Health System Recognized as an American Heart Association Fit-Friendly Worksite
3. Beaumont Cardiologist Kavitha Chinnaiyan, M.D., Receives Excellence in Research Award
4. Beaumont cardiologist Kavitha Chinnaiyan, M.D., receives excellence in research award
5. Beaumont receives national green award
6. Beaumont recipient of 2013 Dove Award from the Arc of Oakland County
7. Beaumont Childrens Hospital pediatrician inducted into Legends of Neonatology Hall of Fame
8. Beaumont doctors call for training to reduce sudden cardiac arrest fatalities in schools
9. Gulfside Dental Visits First Steps Daycare in Beaumont, TX
10. Gulfside Dental Celebrating Seniors Mardi Gras at Beaumont Civic Center
11. Gulfside Dental Now Offers LUMINEERS in Beaumont, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Comparemedicalinsurance.info has released a new blog ... who have health problems. , A pre-existing medical ... clients. No medical exam life insurance plans offer a ... a lot easier. , No medical exam life ... temporary protection, while others will insure the client for ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Discount-Dress.com, an ... and women’s special occasion outfits, is doing its best ... its dresses at discounted rates, up to 75% off. ... new blog . Also, it has unveiled many ... cocktail party dresses, gorgeous lace wedding dresses, purple prom ...
(Date:7/24/2014)... July 24, 2014 Follow ... a rapidly expanding sector in the in-vitro diagnostics ... collection devices, new detection technologies, computers, and automation ... versatility, and speed. In addition to disease diagnosis, ... benefits in patient stratification, drug regimen selection, therapeutic ...
(Date:7/24/2014)... Hanover, MA (PRWEB) July 24, 2014 ... Foundation will be on hand to provide educational and ... 11th Annual Meeting next week in Colorado Springs. , ... from some of the most renowned neurointerventional research ... problem solving and innovating together (with or at) symposiums, ...
(Date:7/24/2014)... July 24, 2014 “To care for him ... and his orphan.” The inspired quote is attributed to Abraham ... of Veterans Affairs (VA). And yet the reality of Lincoln’s ... in exchange for their service in times of conflict, leaves ... represents many veterans locked in a battle they never expected ...
Breaking Medicine News(10 mins):Health News:Life Insurance Without Examinations for Clients Who Have Pre-Existing Medical Conditions 2Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 3Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 4Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 5
... 19 DaVita Inc., a,leading provider of kidney ... (CKD) and kidney failure, today announced that they ... patients,against influenza (flu). Today,s announcement highlights DaVita,s proven ... services, setting the standard for,superior clinical care. , ...
... Lecture for Healthcare ProfessionalsVOORHEES, N.J., Jan. 19 ... being seen in older adults, especially among residents ... complicated by the emergence of a virulent strain ... rates of morbidity and mortality. Implementing strategies for ...
... Center invites women of all ages to attend Girls, ... 6:00 p.m. at Northgate Mall. The event, sponsored by ... more. The Northwest Hospital booth will feature free ... well as body mass index (BMI) and waist measurement ...
... Educational CD provides veterinarians with a new way to understanding and ... ... January 19, 2009 -- Merial today announced the availability of an ... the complex subject of heartworm prevention and treatment in dogs. Launched ...
... Inc., a world leader in handheld x-ray technologies, announced ... patent for its NOMAD Handheld X-ray System. The latest ... having all components of the x-ray system in the ... the world,s first handheld x-ray system. Aribex was previously ...
... Fla., Jan. 19 As the unemployment rate grows, ... who are coping with the,loss of health insurance. COBRA ... but while many workers have the right to,purchase such ... cost is,often prohibitively high. A November 2008 study by ...
Cached Medicine News:Health News:DaVita 'Flu Fighter Program' Vaccinates 85 Percent of Patients 2Health News:Clostridium difficile Infection in Long-Term Care: Tailored Approaches to Management 2Health News:Northwest Hospital Sponsors Girls' Day Out Event at Northgate Mall 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 3Health News:Aribex(R) Awarded Patents for Handheld X-ray 2Health News:Is Your Business Ready for the COBRA Premium Subsidy? 2
(Date:7/24/2014)... DALLAS , July 24, 2014  Market ... of IVD Insights™ LabFile , a data ... the US clinical laboratory universe and identifying target ... is a proprietary database that provides IVD manufacturers ... clinical tests, relying on clear and consistent definitions ...
(Date:7/24/2014)... 24, 2014 HIGHLIGHTS:Q2 2014 Results (all ... , Reported sales increased 3% to $701 million.  Sales grew ... added one percentage point to sales growth. , By ... in Applied and 1% in SAFC Commercial. , Reported ... an increase of 13%.  Adjusted diluted EPS in Q2 2014 ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... Alpharma Inc.,(NYSE: ALO ), a ... its Phase III pivotal efficacy trial that ... naltrexone,hydrochloride) capsules provided significant pain relief in ... osteoarthritis of the hip or knee compared,to ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the American College ... & Convention Center in Orlando., ... October 7, 2008 from 10:30 a.m. - 4:00 p.m. ...
Cached Medicine Technology:Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: